Patents by Inventor Philip B. Graham

Philip B. Graham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10813926
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: October 27, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Publication number: 20200222408
    Abstract: Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I): or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
    Type: Application
    Filed: December 5, 2019
    Publication date: July 16, 2020
    Inventors: Amanda T. Wagner, James V. Cassella, Philip B. Graham, Virginia Braman, Vinita Uttamsingh, Jana Von Hehn, Colleen E. Hamilton
  • Publication number: 20200216396
    Abstract: Disclosed herein are deuterated forms of 2-ethylamino-8-fluoro-3-methyl-1-oxo-1,2-dihydro-isoquinoline-4-carboxylic acid ((S)-cyclopropyl-phenyl-methyl)-amide (also referred to herein as SJB-01) and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: January 3, 2020
    Publication date: July 9, 2020
    Inventors: David J. Turnquist, Jayachandra P. Reddy, Philip B. Graham
  • Patent number: 10561659
    Abstract: Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: February 18, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Amanda T. Wagner, James V. Cassella, Philip B. Graham, Virginia Braman, Vinita Uttamsingh, Jana Von Hehn, Colleen E. Hamilton
  • Publication number: 20200022975
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: July 26, 2019
    Publication date: January 23, 2020
    Applicant: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Publication number: 20190336494
    Abstract: This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disorders with such a morphinan compound in combination with quinidine, or pharmaceutically acceptable salt of either or both thereof.
    Type: Application
    Filed: July 22, 2019
    Publication date: November 7, 2019
    Inventors: Roger D. Tung, Philip B. Graham
  • Patent number: 10406155
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: September 10, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Publication number: 20190160068
    Abstract: Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 30, 2019
    Inventors: Amanda T. Wagner, James V. Cassella, Philip B. Graham, Virginia Braman, Vinita Uttamsingh, Jana Von Hehn, Colleen E. Hamilton
  • Publication number: 20190038618
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: July 16, 2018
    Publication date: February 7, 2019
    Inventors: Philip B. Graham, I. Robert Silverman
  • Publication number: 20180243291
    Abstract: This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disorders with such a morphinan compound in combination with quinidine, or pharmaceutically acceptable salt of either or both thereof.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 30, 2018
    Inventors: Roger D. TUNG, Philip B. GRAHAM
  • Publication number: 20180243290
    Abstract: This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disorders with such a morphinan compound in combination with quinidine, or a pharmaceutically acceptable salt of either or both thereof.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 30, 2018
    Inventors: Roger D. Tung, Philip B. Graham
  • Publication number: 20180208566
    Abstract: This invention relates to deuterated forms of meclizine, and pharmaceutically acceptable salts or hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering meclizine and other Constitutive Androstane Receptor agonists or FGFR3 antagonists.
    Type: Application
    Filed: July 21, 2016
    Publication date: July 26, 2018
    Inventors: Philip B. Graham, Julie F. Liu
  • Patent number: 10022370
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 17, 2018
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Publication number: 20170281616
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 5, 2017
    Applicant: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Patent number: 9655895
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 23, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Publication number: 20160287579
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a al receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: May 6, 2016
    Publication date: October 6, 2016
    Inventors: Philip B. Graham, I. Robert Silverman
  • Patent number: 9340512
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: May 17, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Patent number: 9266837
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: February 23, 2016
    Assignee: Concert Phamaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Publication number: 20150336899
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: June 1, 2015
    Publication date: November 26, 2015
    Inventors: Philip B. Graham, I. Robert Silverman
  • Publication number: 20150328220
    Abstract: The present invention relates to a novel method of treating chronic kidney disease in a patient with macroalbuminuria. The method comprises administering to the patient an effective amount of a compound described herein.
    Type: Application
    Filed: May 14, 2015
    Publication date: November 19, 2015
    Inventor: Philip B. Graham